This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate West Pharmaceutical Services (WST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ABC vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
ABC vs. WST: Which Stock Is the Better Value Option?
ABC vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ABC vs. WST: Which Stock Is the Better Value Option?
West Pharmaceutical (WST) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
MCK vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. WST: Which Stock Is the Better Value Option?
Will West Pharmaceutical Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor West Pharmaceutical.
West Pharmaceutical (WST) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
West Pharmaceutical Services (WST) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 23.61% and 1.68%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Jul 25: SYK, BAX & More
by Urmimala Biswas
Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HSIC vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HSIC vs. WST: Which Stock Is the Better Value Option?
West Pharmaceutical (WST) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ABC vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
ABC vs. WST: Which Stock Is the Better Value Option?
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
West Pharmaceutical Services (WST) Beats Q4 Earnings Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 1.39% and -2.87%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HSIC vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. WST: Which Stock Is the Better Value Option?
West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 7.04% and 0.97%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MedTech Stocks' Q4 Earnings on Feb 16: LH, WST and MDRX
by Zacks Equity Research
Let's take a look at the major MedTech stocks slated to release their fourth-quarter 2016 numbers on Feb 16.